Debiopharm
Chemin Messidor 5-7
Case Postale 5911
Lausanne
CH - 1002
Tel: 41-21-321-0111
Fax: 41-21-321-0169
Website: http://www.debiopharm.com/
213 articles about Debiopharm
-
Debiopharm Enters The Field Of Antibody-Drug Conjugates Through Acquisition Of Phase II Asset From ImmunoGen
5/24/2017
-
BC Platforms Closes USD $10 Million Series B Financing Led By Debiopharm And Tesi To Accelerate Knowledge Platform Development
5/9/2017
-
Debiopharm Uses Cutting-Edge ClinTrial App Mobile Application From ClinOne In Clinical Study
3/23/2017
-
Debiopharm Innovation Fund: The New Name And Investment Strategy Of Debiopharm Diagnostics
3/7/2017
-
Debiopharm Release: Biopharma Announces Positive Phase 2 Clinical Trial With Debio 1450 In ABSSSI Patients
1/10/2017
-
Debiopharm's Triptorelin 6-Month Formulation Receives Approval For The Treatment Of Central Precocious Puberty (CPP) In Europe
1/9/2017
-
Debiopharm Reaches Important Development Milestones For Its Staphylococcus-Selective Antibiotic Debio 1450
10/25/2016
-
Debiopharm Reaches Important Development Milestones For Its Staphylococcus-Selective Antibiotic Debio 1450
10/25/2016
-
Debiopharm Announces Clinical Collaboration With Merck KGaA, Darmstadt, Germany, And Pfizer In Cancer Immunotherapy
10/20/2016
-
The Japanese Cancer Association And Debiopharm Announce Winners Of The 2016 JCA-Mauvernay Award
10/7/2016
-
Debiopharm Dumps Double Digit Millions Into Canadian Startup GenePOC
8/31/2016
-
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1143 In Ovarian Cancer
6/7/2016
-
FDA Grants Orphan Drug Designation To Debiopharms IAP Inhibitor Debio 1143 In The Treatment Of Ovarian Cancer
6/2/2016
-
Debiopharm Donates To IMD To Promote Best Practice In Family Business Philanthropy
5/11/2016
-
Debiopharm Announces Presentation At AACR Of Non-Clinical Data Relating To Its Targeted Investigational Compound Debio 1347/CH5183284, A Selective FGFR 1,2,3 Inhibitor
4/15/2016
-
Debiopharm To Present The Latest Findings On Debio 1450 At ECCMID
4/8/2016
-
Debiopharm Has Won Its Patent Infringement Suit For Elplat Against Nippon Kayaku Co., Ltd.
3/4/2016
-
Debiopharm And EORTC Announce A Collaboration To Investigate Triptorelin For Treatment Of Salivary Gland Cancers
1/13/2016
-
United Laboratories Inc. And Debiopharm Announce The Launch Of Pamorelin LA In The Philippines
12/7/2015
-
Debiopharm's Partner Yakult Honsha Announces Elplat Approbation In Gastric Cancer In Japan
11/24/2015